Forma to receive $2.0M up front, $17.5M upon regulatory, approval & first commercial sale milestones, ~$215.5M in development & commercial milestones along with royalties
Rigel will lead the launch & commercialization of olutasidenib in the US & is planning for outside the US with potential partners. The collaboration will advance Rigel’s hematology-oncology portfolio & will use commercial capabilities for a new therapy
In an interim analysis of the P-II registrational study, olutasidenib showed 33% CR+CRh in mIDH1+ r/r AML patients., 18mos. survival (87%) & the median duration of CR+CRh (not reached) and showed durable response & a favorable tolerability profile. The US FDA has accepted olutasidenib’s NDA with an anticipated PDUFA date on Feb 15, 2023
Ref: Rigel | Image: Rigel Pharmaceuticals
